Company intelligence / Profile preview
Clexio Biosciences
Petach Tikva, Jerusalem Area, Israelclexio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead drug candidate CLE-100 is in Phase 2 multicenter studies in the United States for Major Depressive Disorder. CLE-400 has completed Multiple Ascending Dose studies and is Phase 2 ready for Chronic Pruritus indications. CLE-500 is in Phase 1 for Cluster Headache. CLE-600 is in Phase 2 for Parkinson's Disease. CLE-905 has completed IND enabling activities with First-In-Human Phase 1 study expected to start soon.
- Therapeutic areas
- DermatologyPsychiatryNeurology
- Modalities
- Small moleculesdrug-device combinations
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Genetika+ (partnering to screen and characterize Clexio's antidepressant pipeline using Genetika+'s iPSC-derived neurons platform)
Beyond the preview
Go deeper on Clexio Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clexio Biosciences.